Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $44,850 | 4 | 92.9% |
| Consulting Fee | $3,425 | 1 | 7.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $44,850 | 4 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $3,425 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,425 | 1 | AstraZeneca Pharmaceuticals LP ($3,425) |
| 2019 | $1,736 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,736) |
| 2017 | $43,114 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($43,114) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| 10/18/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | RYDAPT (Drug) | — | In-kind items and services | $1,257.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: HEMATOLOGY | ||||||
| 02/20/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | RYDAPT (Drug) | — | In-kind items and services | $479.14 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: HEMATOLOGY | ||||||
| 05/03/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | RYDAPT (Drug) | — | In-kind items and services | $21,557.00 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: HEMATOLOGY | ||||||
| 03/31/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | RYDAPT (Drug) | — | In-kind items and services | $21,557.00 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: HEMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $43,114 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,736 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 91 | 246 | $68,804 | $16,588 |
| 2022 | 3 | 120 | 331 | $89,476 | $21,591 |
| 2021 | 2 | 91 | 329 | $26,805 | $21,306 |
| 2020 | 3 | 86 | 316 | $31,210 | $19,987 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 168 | $46,536 | $10,004 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 56 | $16,240 | $5,439 | 33.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 22 | $6,028 | $1,145 | 19.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 54 | 241 | $64,588 | $13,422 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 54 | 78 | $22,620 | $7,297 | 32.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 12 | $2,268 | $872.40 | 38.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 54 | 267 | $18,658 | $15,150 | 81.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 37 | 62 | $8,147 | $6,157 | 75.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 37 | 222 | $18,458 | $12,060 | 65.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 38 | 83 | $10,661 | $6,628 | 62.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $2,091 | $1,299 | 62.1% |
About Dr. Mrinal Patnaik, MD
Dr. Mrinal Patnaik, MD is a Internal Medicine healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1376727115.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mrinal Patnaik, MD has received a total of $48,275 in payments from pharmaceutical and medical device companies, with $3,425 received in 2024. These payments were reported across 5 transactions from 2 companies. The most common payment nature is "" ($44,850).
As a Medicare-enrolled provider, Patnaik has provided services to 388 Medicare beneficiaries, totaling 1,222 services with total Medicare billing of $79,472. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hematology
- Location Rochester, MN
- Active Since 12/27/2007
- Last Updated 08/19/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1376727115
Products in Payments
- RYDAPT (Drug) $44,850
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Rochester
Dr. Ben George, M.d, M.D
Internal Medicine — Payments: $729,795
John Kisiel, M.d, M.D
Internal Medicine — Payments: $550,377
Gregory Poland, M.d, M.D
Internal Medicine — Payments: $532,099
Christopher Ritchlin, Md, MD
Internal Medicine — Payments: $512,889
Scott Feitell, D.o, D.O
Internal Medicine — Payments: $471,187
Prashant Kapoor, Md, MD
Internal Medicine — Payments: $403,295